AVITA Medical, Inc.
NASDAQ:RCELMedical - Devices
+$0.00 today
- Market cap
- $418.11M
- Beta
- 1.86
- P/E (TTM)
- -0.0
- EPS (TTM)
- -$148.45
Volume 0.72M
Average 0.24M
RCEL Total Current Liabilities
All obligations due within one year.
AVITA Medical, Inc.NASDAQ: RCEL
Total Current Liabilities · Q1 FY2026 · quarter ended Mar 2026
Total current liabilities rises 190.4% from a year ago
Total current liabilities stood at $66.67M at the end of Q1 FY2026, up 190.4% from a year earlier and up 6.4% from the prior quarter. Over 3 fiscal years it compounded at +80.3% a year.
Context
- Total current liabilities amounted to 129.3% of total assets at the end of Q1 FY2026, up 96.3 pp from a year earlier.
- Total current liabilities increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total current liabilities keeps rising in the next quarterly balance sheet after a +190.4% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 62.68M USD
- Year-over-year change
- +210.9%
- 4-year CAGR
- +61.8%
| Period | Period end | Total Current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 62.68M | +210.9% |
| FY2024 | 2024-12-31 | 20.16M | +52.7% |
| FY2023 | 2023-12-31 | 13.2M | +23.4% |
| FY2022 | 2022-12-31 | 10.69M | +16.9% |
| FY2021 | 2021-12-31 | 9.15M | — |
Total Current Liabilities vs competitors
How RCEL compares with its peers on the latest reported figures
- RCEL's Mar 2026 total current liabilities of $66.67M is the highest of the 9 companies compared; the peer median is $12.95M.
- Its year-over-year change of +190.4% is the highest of 9, against a peer median of +4.3%.
- Total current liabilities amounts to 129.3% of total assets for RCEL, versus a peer median of 15.5%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $66.67M | +190.4% | +80.3% | 129.3% | |
| Mar 2026 | $29.39M | -19.6% | +50.3% | 86.2% | |
| Mar 2026 | $18.77M | -36.5% | +24.7% | 24.1% | |
| Mar 2026 | $16.12M | +14.8% | +0.7% | 7.4% | |
| Mar 2026 | $15.75M | +69.2% | +5.8% | 7.0% | |
| Mar 2026 | $10.15M | +27.3% | +10.0% | 16.8% | |
| Mar 2026 | $9.45M | -0.7% | -0.4% | 15.0% | |
| Mar 2026 | $6.78M | +9.3% | -1.1% | 16.0% | |
| Mar 2026 | $4.25M | -41.9% | -34.4% | 4.2% | |
| Peer median (excluding RCEL) | $12.95M | +4.3% | +3.3% | 15.5% | |
Competitors are the stored peer set for RCEL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 55.51M | 18.16M | 22.12M | 14.05M | 10.24M |
| Short-term Investments | 29.65M | 61.18M | 66.94M | 21.84M | 7.94M |
| Net Receivables | 3.43M | 4.96M | 7.92M | 11.96M | 9.09M |
| Inventory | 2.13M | 2.13M | 5.6M | 7.27M | 6.93M |
| Other Current Assets | 290K | 362K | 18K | 1.88M | 1.29M |
| Total Current Assets | 92.13M | 87.46M | 104.01M | 57M | 35.49M |
| Property, Plant & Equipment (Net) | 2.81M | 2.05M | 4.32M | 13.59M | 11.53M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 443K | 465K | 487K | 5.57M | 5.65M |
| Long-term Investments | 19.69M | 6.93M | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 942K | 1.36M | 2.83M | 3.55M | 3.73M |
| Total Non-current Assets | 23.88M | 10.81M | 7.63M | 22.71M | 20.9M |
| Total Assets | 116.02M | 98.26M | 111.64M | 79.71M | 56.39M |
| Account Payables | 2.71M | 3M | 3.79M | 6.29M | 8.96M |
| Short-term Debt | 0 | 0 | 0 | 0 | 42.98M |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 33K | 0 | 0 |
| Other Current Liabilities | 355K | 456K | 506K | 2.51M | 9.81M |
| Total Current Liabilities | 9.15M | 10.69M | 13.2M | 20.16M | 62.68M |
| Long-term Debt | 0 | 0 | 39.81M | 42.25M | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 698K | 357K | 324K | 290K |
| Other Non-current Liabilities | 1.33M | 1.83M | 7.51M | 9.65M | 7.94M |
| Total Non-current Liabilities | 2.25M | 2.83M | 49.39M | 55.05M | 10.37M |
| Total Liabilities | 11.39M | 13.52M | 62.58M | 75.21M | 73.04M |
| Common Stock | 3K | 3K | 3K | 3K | (1.29M) |
| Retained Earnings | (235.92M) | (262.59M) | (297.97M) | (359.81M) | (408.4M) |
| Accumulated OCI | 8.06M | 7.63M | (1.89M) | (1.94M) | (1.37M) |
| Other Stockholders Equity | 0 | (127K) | (1.13M) | (1.32M) | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 104.62M | 84.74M | 49.06M | 4.5M | (16.65M) |
| Total Debt | 1.64M | 918K | 42.41M | 45.99M | 46.05M |
| Net Debt | (53.87M) | (17.25M) | 20.29M | 31.94M | 35.81M |
AVITA Medical, Inc.
NASDAQ:RCEL
Intrinsic Alpha fair value
Locked
Current Price
$16.83
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.